Use of HIFU for Tremor-Dominant Parkinson’s Disease: A Patient Success Story - Scorecard - MDSpire

Use of HIFU for Tremor-Dominant Parkinson’s Disease: A Patient Success Story

HIFU is an FDA-approved procedure that uses highly focused ultrasound waves to target a small area in the brain’s thalamus responsible for tremors.

  • April 17, 2026

  • 7 min

Share

Clinical Scorecard: Use of HIFU for Tremor-Dominant Parkinson’s Disease: A Patient Success Story

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingConsider specifying if other facilities also provide HIFU.

Key Highlights

  • immediate_improvement

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • f
      • o
      • l
      • l
      • o
      • w
      • -
      • u
      • p
      • t
      • i
      • m
      • e
      • l
      • i
      • n
      • e
      • s
      • a
      • n
      • d
      • a
      • s
      • s
      • e
      • s
      • s
      • m
      • e
      • n
      • t
      • s
      • .

      Risks

        Patient & Prescribing Data

        Patients with tremor-dominant Parkinson’s disease.

        HIFU offers a non-invasive alternative to Deep Brain Stimulation (DBS) for managing tremors.

        Clinical Best Practices

        • multidisciplinary_team

        Related Resources & Content

        Original Source(s)

        Use of HIFU for Tremor-Dominant Parkinson’s Disease: A Patient Success Story

        • April 17, 2026

        Related Content

        Does Pediatric Readiness Reduce ED Imaging?

        Hospitals with stronger pediatric emergency capability used less imaging overall, but differences by insurance status and race and ethnicity remained.

        Do Sitting Patterns Matter?

        Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

        FDA Cites Manufacturing Issues for Cytisinicline

        Application supported by Phase 3 smoking-cessation data and long-term safety findings.